UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors
  • Mar

    26

    New Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasis Presented at the 2022 AAD Annual Meeting

    Mar

    15

    Voices on Value: Building a Sustainable Healthcare System Together – Our U.S. Sustainable Access and Pricing Transparency Report

    Last year, UCB launched its Voices on Value blog series to foster a dialogue around how to make our health system better, stronger, and more accessible now and in the future. To advance this dialogue, UCB is releasing its first-ever U.S. Sustainable Access and Pricing Transparency Report, which underscores UCB’s commitment to an innovative, competitive, and value-based system. 

    Mar

    07

    UCB Completes Acquisition of Zogenix, Inc.

    Feb

    22

    Partnering for Greater Impact with Microsoft in R&D

    At UCB, our aim is to amplify the power of scientific innovation through digital transformation, ensuring we deliver the best individual experience so patients can live their best lives. As part of that effort, we are integrating artificial intelligence (AI) across the research and development organization to bring accelerated solutions to patients with unmet needs. 

    Feb

    04

    UCB announces positive data in myasthenia gravis with zilucoplan phase 3 study results

    Jan

    21

    Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

    Jan

    19

    UCB to acquire Zogenix

    Jan

    18

    Positive Top-Line Results for bimekizumab in Phase 3 Non-Radiographic Axial Spondyloarthritis Study

    Dec

    16

    Positive Top-Line Results for Bimekizumab in Phase 3 Ankylosing Spondylitis Trial

    Dec

    10

    UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis